Last updated: September 2, 2026
Empagliflozin, marketed primarily as Jardiance by Boehringer Ingelheim and Eli Lilly, has evolved from a type 2 diabetes product into a cardiovascular and renal franchise. Its commercial trajectory has been driven more by heart-failure and chronic-kidney-disease adoption than by diabetes alone. The principal strategic risk is the transition from a high-growth, multi-indication product to a post-core-patent market facing generic competition in the United States and Europe.
Lilly-reported Jardiance revenue rose from approximately $2.5 billion in 2022 to about $3.0 billion in 2023 and approximately $3.7 billion in 2024. These figures represent Lilly’s reported share, not total global Jardiance revenue. Boehringer Ingelheim reports its alliance economics separately, so no single public figure captures consolidated brand sales.[1][2]
What is empagliflozin and which markets drive demand?
Empagliflozin is an oral sodium-glucose cotransporter 2, or SGLT2, inhibitor. It reduces renal glucose reabsorption and has demonstrated benefits across diabetes, heart failure, and chronic kidney disease.
| Attribute |
Empagliflozin |
| Active ingredient |
Empagliflozin |
| Primary brand |
Jardiance |
| Combination brands |
Synjardy, Synjardy XR, Glyxambi, Trijardy XR |
| Originators |
Boehringer Ingelheim and Eli Lilly |
| Initial U.S. approval |
August 2014 |
| Therapeutic classes |
Diabetes, heart failure, chronic kidney disease |
| U.S. dosage strengths |
10 mg and 25 mg |
| Core mechanism |
SGLT2 inhibition |
| Main competitors |
Dapagliflozin, canagliflozin, ertugliflozin |
| U.S. regulatory pathway |
New drug application |
| Biosimilar relevance |
None; empagliflozin is a small molecule |
Jardiance was initially approved to improve glycemic control in adults with type 2 diabetes. Its commercial positioning expanded after cardiovascular-outcomes data and later heart-failure approvals. The FDA approved Jardiance to reduce cardiovascular death in adults with type 2 diabetes and established cardiovascular disease in 2016. Subsequent approvals covered heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, and chronic kidney disease.[3]
Heart failure and kidney disease expand the addressable population because treatment can be prescribed independently of diabetes status. That expansion also changes the competitive basis. Physicians and payers increasingly evaluate empagliflozin against dapagliflozin on heart-failure and renal outcomes, not only glycated hemoglobin reduction.
How large is the empagliflozin market?
The commercial market is divided between branded Jardiance, branded combinations, regional products, and future generic empagliflozin. Jardiance remains the principal value driver.
Lilly-reported financial trajectory
| Fiscal year |
Lilly-reported Jardiance revenue |
Approximate year-over-year change |
| 2021 |
About $2.2 billion |
Not comparable |
| 2022 |
About $2.5 billion |
Approximately 12% |
| 2023 |
About $3.0 billion |
Approximately 22% |
| 2024 |
About $3.7 billion |
Approximately 23% |
Sources report Lilly’s Jardiance revenue within the company’s alliance accounting. Boehringer Ingelheim separately reports its commercial results. The combined economics are therefore higher than Lilly’s reported figure, but an exact consolidated brand total is not disclosed in a unified public statement.[1][2]
What explains the revenue growth?
The main growth drivers are:
- Expanded heart-failure labeling.
- Chronic-kidney-disease treatment uptake.
- Greater use in patients without diabetes.
- Increased guideline support for SGLT2 inhibitors.
- Higher diagnosis and treatment rates in chronic kidney disease.
- Continued diabetes market growth before generic erosion.
The product also benefits from a broad prescriber base. Primary-care physicians, endocrinologists, cardiologists, and nephrologists can all initiate or maintain therapy. This reduces dependence on one specialty, although it increases the importance of payer coverage and guideline positioning.
What could reduce future revenue?
Revenue pressure is likely to come from three sources:
- U.S. generic entry after key compound and formulation protections weaken.
- Dapagliflozin competition in heart failure and chronic kidney disease.
- Price controls, rebates, and payer preference for lower-cost SGLT2 products.
The revenue decline is unlikely to be immediate across all indications. Branded prescriptions may remain significant where physicians prefer Jardiance, where combination products are used, or where originators secure favorable formulary terms. Generic substitution will be strongest in routine type 2 diabetes treatment, where therapeutic alternatives are numerous.
When does empagliflozin lose exclusivity?
Jardiance’s regulatory exclusivity and patent exclusivity have different timelines.
| Exclusivity category |
Timing or status |
| U.S. new chemical entity exclusivity |
Generally expired in 2019 |
| Pediatric exclusivity |
May extend applicable exclusivity or patent dates by six months where granted |
| Core U.S. compound patent |
Publicly associated with expiration in 2025, subject to listed patent scope and adjustments |
| Later formulation or method patents |
May extend selected protection into the 2030s |
| European compound protection |
Generally reaches the mid-2020s, with country-specific supplementary protection certificate analysis |
| Generic status |
Dependent on ANDA approval, Paragraph IV litigation, settlements, and enforceable patent claims |
The core U.S. composition-of-matter patent commonly associated with empagliflozin is U.S. Patent No. 7,579,449. Public patent databases identify an expiration date in August 2025 before any applicable pediatric adjustment. The Orange Book must be reviewed for the active patent list, expiration dates, pediatric extensions, and drug-substance or drug-product designations.[4][5]
The practical exclusivity date is not necessarily the last expiration date appearing in the Orange Book. A generic applicant may challenge listed patents through Paragraph IV certification. If the patent holder sues within the statutory period, FDA approval can be stayed for up to 30 months, unless the litigation is resolved earlier or the stay is otherwise altered.[6]
What patents protect Jardiance and empagliflozin formulations?
The patent estate includes more than the original compound patent. It may include:
- Empagliflozin composition-of-matter claims.
- Crystalline-form or solid-state claims.
- Tablet-composition claims.
- Processes for manufacturing empagliflozin.
- Combination products containing metformin or linagliptin.
- Methods of treating heart failure.
- Methods of treating chronic kidney disease.
- Dosing and patient-selection claims.
Compound patents
The compound patent provides the broadest protection because it covers empagliflozin as a chemical entity. Once that protection expires, an ANDA applicant can generally seek approval for the same active ingredient, subject to remaining listed patents.
Formulation patents
Formulation claims can cover the tablet, excipients, particle properties, dissolution characteristics, or dosage form. Their commercial value depends on whether a generic applicant can design around the claims while maintaining pharmaceutical equivalence.
Formulation patents usually create less durable protection than a composition-of-matter patent. They can delay a particular product design but may not prevent all generic entry.
Method-of-use patents
Method patents are commercially important because Jardiance’s value now extends beyond diabetes. Claims directed to heart failure or chronic kidney disease may cover treatment methods, patient populations, or clinical outcomes.
Their enforcement value is narrower than compound claims. A generic applicant may seek a “skinny label” that omits patented indications under the FDA’s section viii pathway. The effectiveness of that strategy depends on the wording of the patent claims, the proposed label, prescribing behavior, and inducement evidence.[6]
Combination-product patents
Synjardy and Synjardy XR combine empagliflozin with metformin. Glyxambi combines empagliflozin with linagliptin. Trijardy XR combines empagliflozin, linagliptin, and metformin.
These products have separate regulatory applications and can have separate Orange Book listings. A generic competitor to Jardiance does not automatically create an approved substitute for each combination product. Combination products may retain value after standalone empagliflozin faces competition.
What is the Orange Book status of Jardiance?
Jardiance is an FDA-approved small-molecule drug listed in the Orange Book. The Orange Book identifies approved strengths, dosage forms, reference listed drug status, and patents submitted by the NDA holders.[4]
The relevant diligence points are:
| Orange Book issue |
Commercial significance |
| Reference listed drug |
Establishes the product for ANDA comparison |
| 10 mg and 25 mg tablets |
Allows strength-specific generic applications |
| Listed drug patents |
Define potential Paragraph IV targets |
| Method-of-use listings |
May support indication-specific litigation |
| Pediatric extension |
Can affect the earliest permissible approval date |
| Combination NDAs |
Require separate analysis for Synjardy, Glyxambi, and Trijardy XR |
Orange Book status does not by itself establish that every listed patent is enforceable or infringed. Patent scope must be assessed against the proposed generic formulation, label, manufacturing process, and indication set.
Which companies are challenging empagliflozin exclusivity?
Generic competition is expected from major ANDA developers, including large Indian, U.S., and European manufacturers. Public patent-litigation activity involving Jardiance-related products has included challenges by companies seeking approval for empagliflozin or empagliflozin combinations.
Potential participants in the competitive field include:
- Teva Pharmaceuticals.
- Sandoz.
- Lupin.
- Zydus.
- Torrent Pharmaceuticals.
- Aurobindo-related entities.
- Dr. Reddy’s Laboratories.
- Sun Pharma.
- MSN Laboratories.
- Other regional ANDA and European generic manufacturers.
The relevant legal event is not merely the filing of an ANDA. The market-entry sequence normally involves:
- ANDA filing.
- Paragraph IV notice to the patent holders.
- Patent-holder litigation.
- A 30-month stay or earlier resolution.
- FDA tentative approval or final approval.
- Settlement, license, authorized generic arrangement, or launch.
What patent litigation affects Jardiance?
Jardiance litigation risk centers on the timing and scope of Paragraph IV challenges. Originators may sue over the core compound patent, formulation patents, or indication-specific patents. Generic applicants may challenge validity, enforceability, patent listing propriety, or infringement.
The highest-value disputes are those involving:
- The 10 mg and 25 mg Jardiance tablets.
- Heart-failure indications.
- Chronic-kidney-disease indications.
- Synjardy and other combination products.
- Manufacturing routes and solid-state forms.
A settlement can permit entry before the latest patent expiration. The economic terms may include a negotiated launch date, an authorized generic arrangement, a royalty, or restrictions tied to specific indications. Settlement terms are often confidential, limiting external assessment of the exact effective entry date.
No final court judgment should be inferred solely from a Paragraph IV filing or a docket entry. The operative commercial date is the date established by a final judgment, settlement, license, or FDA approval decision.
Does empagliflozin face biosimilar risk?
Empagliflozin has no biosimilar risk because it is a chemically synthesized small molecule. Competition proceeds through the ANDA pathway rather than the abbreviated biologics license application pathway.
The relevant risks are:
- Abbreviated generic tablets.
- Authorized generics.
- Generic combination products.
- Therapeutic substitution by dapagliflozin.
- Payer-driven switching.
- Formulary exclusion or higher patient cost sharing.
This distinction matters for forecasting. Generic entry can produce rapid price compression and high substitution rates, while biosimilar entry typically depends more heavily on interchangeability, provider administration, and biologic manufacturing capacity.
How does empagliflozin compare with dapagliflozin?
Dapagliflozin, marketed as Farxiga in the United States, is the closest branded comparator.
| Issue |
Empagliflozin |
Dapagliflozin |
| Originator |
Boehringer Ingelheim and Eli Lilly |
AstraZeneca |
| Core brand |
Jardiance |
Farxiga |
| Diabetes use |
Yes |
Yes |
| Heart-failure use |
Broad heart-failure labeling |
Broad heart-failure labeling |
| Chronic-kidney-disease use |
Yes |
Yes |
| Main commercial advantage |
Strong cardiovascular brand recognition and broad alliance resources |
Strong renal and heart-failure positioning |
| Generic exposure |
Core protection reaches the mid-2020s |
Patent and litigation profile differs by jurisdiction |
| Biosimilar risk |
None |
None |
Empagliflozin and dapagliflozin are clinically differentiated more by trial populations, labeling details, payer contracts, and physician familiarity than by mechanism. In a post-patent market, price and formulary status may become more important than modest differences in clinical positioning.
Canagliflozin remains relevant in diabetes and cardiovascular care, but its renal and fracture-related safety history has affected its competitive position. Ertugliflozin is a smaller commercial competitor.
What generic entry scenarios exist for empagliflozin?
Scenario 1: At-risk or early licensed entry
A generic manufacturer launches after resolving litigation or receiving a license. Price erosion begins before all secondary patents expire. This scenario creates the largest near-term revenue shock.
Scenario 2: Staggered entry by indication
Generics enter for diabetes while heart-failure or kidney-disease method claims remain contested. The commercial effect depends on whether prescribers use the generic product for protected indications.
Scenario 3: Multiple-generic launch
Several ANDA approvals occur near the same date. Wholesale acquisition cost and net prices decline rapidly, with market share shifting toward the lowest-cost suppliers.
Scenario 4: Delayed launch from patent litigation
The core patent or a surviving formulation claim delays FDA approval. Branded Jardiance retains substantial revenue until the litigation resolves.
Scenario 5: Authorized generic strategy
The originators or a partner launch an authorized generic. This can reduce the incentive for independent generics to launch aggressively and allows the originator alliance to retain part of the post-expiry economics.
How strong is the empagliflozin patent estate?
The estate is strongest for the original chemical compound and weaker for later secondary protections.
| Patent category |
Relative strength |
Expected commercial effect |
| Composition of matter |
High before expiry |
Blocks products containing empagliflozin |
| Tablet formulation |
Moderate |
May delay or narrow generic design options |
| Solid-state form |
Moderate to high if difficult to design around |
Can create manufacturing and equivalence barriers |
| Manufacturing process |
Variable |
Relevant only if the generic uses a covered process |
| Heart-failure methods |
Moderate |
Depends on label and inducement evidence |
| Kidney-disease methods |
Moderate |
May support indication-specific enforcement |
| Combination products |
Variable |
Protects specific branded combinations, not necessarily standalone Jardiance |
The strategic weakness is timing. Once the foundational compound patent expires, secondary patents must withstand validity and design-around challenges. Clinical-outcome method patents may have more litigation value than direct market-blocking value because they do not always prevent approval of a product labeled for unpatented uses.
What manufacturing and geographic barriers affect empagliflozin?
Empagliflozin is an oral small molecule, so manufacturing barriers are lower than for biologics or complex injectables. Generic manufacturers still must establish:
- API purity and impurity control.
- Solid-state consistency.
- Bioequivalence.
- Tablet dissolution.
- Stability.
- Commercial-scale supply.
- Regulatory compliance at API and finished-dose facilities.
Geographic protection differs by country. U.S. patent rights, European patents, supplementary protection certificates, Japanese patents, and national litigation outcomes do not move in parallel. A company can face U.S. generic entry while retaining protection in selected European or Asian markets.
Export controls and regulatory inspections can affect supply, but they are not substitutes for patent protection. The greatest manufacturing advantage belongs to suppliers with validated API capacity, multiple qualified plants, and established regulatory histories.
What is the FDA regulatory status of empagliflozin?
Jardiance is FDA approved for:
- Glycemic control in adults with type 2 diabetes.
- Reduction of cardiovascular death in specified adults with type 2 diabetes and cardiovascular disease.
- Reduction of cardiovascular death and hospitalization for heart failure in specified adult heart-failure populations.
- Reduction of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease at risk of progression, subject to the approved label and indication language.
The regulatory expansion materially increased the product’s market size. It also increases label complexity for generic applicants because the proposed labeling may require indication carve-outs where method-of-use patents remain in force.[3]
What revenue exposure do Boehringer Ingelheim and Eli Lilly face?
Empagliflozin remains one of the most financially important products in the Boehringer-Lilly alliance. For Lilly, the product is a major established-growth brand but is smaller than Mounjaro, Zepbound, Trulicity, and newer incretin assets. For Boehringer, Jardiance is a core Human Pharma product and a significant contributor to alliance revenue.
The exposure has three dimensions:
- Direct Jardiance price and volume erosion.
- Spillover into Synjardy, Glyxambi, and Trijardy XR.
- Repricing of SGLT2 class economics as generic empagliflozin and dapagliflozin compete.
The alliance can moderate erosion through indication expansion, combination products, contracting, patient-support programs, and lifecycle management. Those tools are unlikely to preserve pre-generic pricing across the entire franchise.
Key Takeaways
- Empagliflozin has expanded from a diabetes drug into a heart-failure and chronic-kidney-disease franchise.
- Lilly-reported Jardiance revenue increased to approximately $3.7 billion in 2024 from about $2.5 billion in 2022.
- The core U.S. compound patent is publicly associated with an August 2025 expiration, subject to applicable extensions and Orange Book analysis.
- Later formulation, manufacturing, combination, and method-of-use patents may affect the exact generic-entry date.
- Empagliflozin faces generic, not biosimilar, competition.
- Dapagliflozin is the principal branded competitor in heart failure and chronic kidney disease.
- The largest financial risk is rapid U.S. price erosion after generic approval, followed by broader international loss of exclusivity.
- Combination products may retain separate patent and regulatory defenses after standalone Jardiance faces competition.
FAQs About Empagliflozin Patent and Market Risk
When can generic Jardiance enter the U.S. market?
Generic entry depends on FDA approval, Paragraph IV litigation, settlements, pediatric extensions, and enforceable Orange Book patents. The core compound protection is publicly associated with August 2025, but the effective launch date may differ.
Is empagliflozin protected by a new chemical entity exclusivity period?
Yes. Jardiance received the standard U.S. five-year new chemical entity exclusivity period after its 2014 approval. That period generally expired in 2019.
Will generic empagliflozin be approved for heart failure?
A generic label may include approved heart-failure indications unless an applicable method-of-use patent requires a carve-out. The final label depends on the ANDA filing, patent certifications, FDA review, and litigation outcome.
Are Synjardy and Trijardy XR protected after Jardiance loses exclusivity?
They may retain separate protection because combination products have distinct NDAs, formulations, patents, and labeling. Standalone empagliflozin generic entry does not automatically establish approval for every combination product.
Is empagliflozin more commercially exposed than dapagliflozin?
The answer depends on patent timing, negotiated entry dates, payer preference, and indication mix. Empagliflozin has substantial revenue exposure because Jardiance is a large alliance product, while dapagliflozin has its own significant heart-failure and renal franchise.
References
- Eli Lilly and Company. (2025). 2024 annual report. https://investor.lilly.com/financial-information/annual-reports
- Boehringer Ingelheim. (2024). Annual report 2023. https://www.boehringer-ingelheim.com
- U.S. Food and Drug Administration. (2024). Jardiance prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- U.S. Patent and Trademark Office. (2009). U.S. Patent No. 7,579,449, C-glucoside compounds. https://patents.google.com/patent/US7579449
- U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/guidance-compliance-regulatory-information-guidances-drugs si
